Equillium, Inc. — Director's Dealing 2025

Feb 20, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Equillium, Inc. (EQ)
CIK: 0001746466
Period of Report: 2025-02-14

Reporting Person: Pruzanski Mark (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-14	Director Stock Option (right to buy)	$0.785	A	12000	Acquired	2029-06-10	Common Stock (12000)	Direct
2025-02-14	Director Stock Option (right to buy)	$6.01	D	12000	Disposed	2029-06-10	Common Stock (12000)	Direct
2025-02-14	Director Stock Option (right to buy)	$0.785	A	24000	Acquired	2030-05-18	Common Stock (24000)	Direct
2025-02-14	Director Stock Option (right to buy)	$2.80	D	24000	Disposed	2030-05-18	Common Stock (24000)	Direct
2025-02-14	Director Stock Option (right to buy)	$0.785	A	20770	Acquired	2031-05-25	Common Stock (20770)	Direct
2025-02-14	Director Stock Option (right to buy)	$6.55	D	20770	Disposed	2031-05-25	Common Stock (20770)	Direct
2025-02-14	Director Stock Option (right to buy)	$0.785	A	20000	Acquired	2032-05-23	Common Stock (20000)	Direct
2025-02-14	Director Stock Option (right to buy)	$2.59	D	20000	Disposed	2032-05-23	Common Stock (20000)	Direct

Footnotes

F1: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F3: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

F4: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

F5: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.